4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid

9RA as a free ligand exists in 2 entries. Examples include: 3H0A 4K6I

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

Name4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
Identifiers4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
FormulaC24 H28 O2
Molecular Weight348.48
Isomeric SMILESCc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C

Chemical Details

Formal Charge0
Atom Count54
Chiral Atom Count0
Chiral Atomsn/a
Bond Count56
Aromatic Bond Count12
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00307 Different stereochemistry
  • approved
  • investigational
DescriptionBexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. [Wikipedia]
  • 4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
  • 4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
  • Bexaroten
  • Bexarotène
  • Bexarotene
Brand Names
  • Bexarotene
  • Targretin
Affected OrganismHumans and other mammals
IndicationUsed orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.
PharmacologyBexarotene is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs). Bexarotene is indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. Bexarotene selectively binds and activates retinoid X receptor subtypes (RXR<sub>α</sub>, RXR<sub>β</sub>, RXR<sub>γ</sub>). RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs), vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Once activated, these receptors function as transcription factors that regulate the expression of genes that control cellular differentiation and proliferation. Bexarotene inhibits the growth <i>in vitro</i> of some tumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression <i>in vivo</i> in some animal models.
Mechanism of actionBexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXR<sub>α</sub>, RXR<sub>β</sub>, RXR<sub>γ</sub>. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL.
Route of administration
  • Oral
  • Topical
  • Anticarcinogenic Agents
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Chemical Actions and Uses
  • Cytochrome P-450 CYP2C9 Substrates
CAS number153559-49-0
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682